FDA submission status update for Vericiguat by Changzhou Pharmaceutical Factory
The FDA has accepted the ANDA220264 application for Vericiguat, submitted by Changzhou Pharmaceutical Factory, which is currently undergoing standard review. Vericiguat, a soluble guanylate cyclase stimulator, is aimed at treating heart failure and is entering a market with established therapies.